RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine's rollout, according to a retrospective analysis.
Study finds RSV vaccine highly effective in protecting older adults against severe disease, hospitalization and death
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV—short for respiratory syncytial virus—vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults,
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complications.
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older first received the shot.
Abrysvo Vaccine Highly Effective Against RSV-Related Hospitalization in Older Adults
The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.
Vaccine about 80 percent effective against severe RSV, hospitalization and death
The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US,
RSV vaccine effective in preventing hospitalizations in older Americans
The authors said the findings should encourage people to get vaccinated against RSV this year. "No vaccine is 100 percent effective. An 80 percent vaccine effectiveness rate is quite impressive and higher than we see,
News Medical8h
Real world data highlights effectiveness of RSV vaccine
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...
What you need to know about the RSV Vaccine
The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...
infectiousdiseaseadvisor.com2d
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
GlobalData on MSN2d
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
MSD (Merck & Co) is planning to get its respiratory syncytial virus (RSV) vaccine, clesrovimab, approved and launched before ...
The Daily Progress5d
Charlottesville vaccine fair offers adults, children chance to catch up
Available vaccines will include flu, COVID, tetanus, HPV, meningococcal, RSV, hepatitis B and Tdap. Drive-through flu shots ...
SchaeffersResearch.com4d
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...